#ai

2 stories

Industry March 27, 2026 · View digest

Pinnacle Medicines Closes $89M Series B for AI-Driven Oral Peptide Pipeline

Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.

Industry March 25, 2026 · View digest

Zealand Pharma Opens U.S. Research Hub in Cambridge, MA

Zealand Pharma announced a new Cambridge research hub combining 25+ years of peptide expertise with AI-driven drug discovery, expanding its obesity and metabolic health pipeline.